Selenoproteins, cholesterol-lowering drugs, and the consequences: revisiting of the mevalonate pathway.
about
Modulation of h(2)s metabolism by statins: a new aspect of cardiovascular pharmacologySignificant changes in circulating microRNA by dietary supplementation of selenium and coenzyme Q10 in healthy elderly males. A subgroup analysis of a prospective randomized double-blind placebo-controlled trial among elderly Swedish citizensStatins stimulate atherosclerosis and heart failure: pharmacological mechanisms.Mechanisms and assessment of statin-related muscular adverse effects.The hypolipidemic and pleiotropic effects of rosuvastatin are not enhanced by its association with zinc and selenium supplementation in coronary artery disease patients: a double blind randomized controlled study.Statins in non-ischaemic cardiomyopathy: an update on our current clinical and pathophysiological understanding.Mevalonate kinase deficiency and neuroinflammation: balance between apoptosis and pyroptosis.SEPP1 polymorphisms modulate serum glucose and lipid response to Brazil nut supplementation.Association of Long-Term Atorvastatin with Escalated Stroke-Induced Neuroinflammation in Rats.Effect of selenium and Q10 on the cardiac biomarker NT-proBNP.Randomized clinical trial: atorvastatin versus placebo in patients with acute exacerbation of mild to moderate ulcerative colitis.Coenzyme Q(10) and selenium in statin-associated myopathy treatment.
P2860
Q27001076-9FC9DC33-C695-4DB4-AB47-A86BB3CC9041Q33610447-696EDDAC-93B9-4846-8F6A-3C2B34CB3069Q34461476-0173B3FE-88B5-4EA4-BF4D-87940EF4E7E7Q34570995-C74CEB1B-845C-4DAE-B6EE-579E8B2F6863Q35192653-78E6ED93-25AE-4AA8-AF5D-049060242568Q37919577-9CBCC3EF-13C8-41D4-B60A-021086B27E20Q38167274-1FD7C4AE-A9DE-4818-B553-E9B2E40E768BQ38684220-6E7A44CD-E052-4A9B-B154-71F3BA36B691Q39474081-8A179C73-852B-4300-BC1E-BBA8497D5026Q44600366-26500184-8D6B-4261-8314-8BB457800F8DQ45852639-F3F661F1-7009-4B81-8BBA-2D30DAE64D5BQ54446305-BC1F0A24-C0A8-42F7-AEFC-589830F387CB
P2860
Selenoproteins, cholesterol-lowering drugs, and the consequences: revisiting of the mevalonate pathway.
description
2004 nî lūn-bûn
@nan
2004 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Selenoproteins, cholesterol-lo ...... ing of the mevalonate pathway.
@ast
Selenoproteins, cholesterol-lo ...... ing of the mevalonate pathway.
@en
Selenoproteins, cholesterol-lo ...... ing of the mevalonate pathway.
@nl
type
label
Selenoproteins, cholesterol-lo ...... ing of the mevalonate pathway.
@ast
Selenoproteins, cholesterol-lo ...... ing of the mevalonate pathway.
@en
Selenoproteins, cholesterol-lo ...... ing of the mevalonate pathway.
@nl
prefLabel
Selenoproteins, cholesterol-lo ...... ing of the mevalonate pathway.
@ast
Selenoproteins, cholesterol-lo ...... ing of the mevalonate pathway.
@en
Selenoproteins, cholesterol-lo ...... ing of the mevalonate pathway.
@nl
P1476
Selenoproteins, cholesterol-lo ...... ing of the mevalonate pathway.
@en
P2093
Bernd Moosmann
Christian Behl
P304
P356
10.1016/J.TCM.2004.08.003
P577
2004-10-01T00:00:00Z